Baird analyst Colleen Kusy raised the firm’s price target on Dianthus (DNTH) to $132 from $67 and keeps an Outperform rating on the shares. The firm’s target increase reflects its positive view on the early GO decisioin CIDP.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus upgraded to Strong Buy from Outperform at Raymond James
- AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks
- Dianthus price target raised to $130 from $100 at Clear Street
- Dianthus announces $400M common stock offering
- Dianthus price target raised to $98 from $81 at Jefferies